foci佛慈品牌怎么样 申请店铺

我要投票 foci佛慈在阿胶行业中的票数:323 更新时间:2025-07-07
foci佛慈是哪个国家的品牌?「foci佛慈」是 兰州佛慈制药股份有限公司 旗下著名品牌。该品牌发源于甘肃,由创始人石爱国在2016期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力foci佛慈品牌出海!将品牌入驻外推网,定制foci佛慈品牌推广信息,可以显著提高foci佛慈产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

foci佛慈怎么样

兰州佛慈制药股份有限公司是一家具有近百年制药历史的市属国有控股上市公司和“中华老字号”企业(股票代码002644)。1929年创建于上海。1956年西迁兰州。2011年上市。目前,公司已发展成为集中药材种植与加工、天然药物与保健品研发、中药现代剂型及保健食品生产销售为一体的西北地区中医药行业的骨干企业。

截止目前,公司拥有4个生产基地、1个在建的医药科技工业园和2家全资子公司。拥有总资产100912万元、净资产71823万元。现有员工1400余人,其中各类工程技术人员400余名。拥有25条生产线,全部通过国家GMP认证,本部生产线还通过澳大利亚TGA组织、日本厚生省和乌克兰产品认证局的认证。现有药品生产批准文号345个,拥有定眩丸、参茸固本还少丸等10个独家产品,1个国家中药保护品种,9项发明专利,常年生产浓缩丸、大蜜丸、片剂等11种剂型的152种中西药产品。佛慈产品以“选材地道、工艺精良、疗效确切、服用方便”享誉中外。“佛慈”牌六味地黄丸、杞菊地黄丸、桂附地黄丸、逍遥丸、香砂养胃丸等系列产品多次被评为“甘肃名牌产品”。公司产品领域不断拓展,以阿胶、本草饮品“肖助理”等为代表的大健康产品陆续上市。“佛慈”注册商标为驰名保护,“岷山”商标为国家工商总局重点保护商标,“宝炉”、“善舒”为甘肃省著名商标。公司与中国中医科学院、瑞典斯德哥尔摩大学、清华大学、甘肃中医学院等多所国内外一流科研院所建立了良好的合作关系。现有甘肃省现代中药制剂工程技术研究中心和中瑞天然植物药和保健品研究中心两个重点研发平台。在漳县、临潭等地拥有当归规范化种植基地,总种植面积近1万亩。佛慈品牌在国内外具有良好的市场基础和广泛的影响力,国际国内销售网络日益完善,产品行销全国,出口到美国、澳大利亚、日本、香港等27个国家和地区,产品国外认证数、海外商标注册数、出口覆盖面、出口品种数长期位居同行业前列,多年来名列中国中成药出口企业十强。佛慈制药是国内首家申请欧盟药品注册的企业,如果浓缩当归丸在欧盟注册成功,并通过欧盟GMP认证,佛慈产品有望以药品身份进入欧盟市场,同时借此建立中药国际化标准。近期,佛慈制药被国家商务部等部委列入国家“首批中医药服务贸易先行先试骨干企业”名单。

近三年,公司将以新区项目为依托、以构建国际国内销售网络为重点,抢抓机遇,加快发展,力争在三年内实现营业收入10亿元,其中中成药出口1000万美元的目标。

Lanzhou foci Pharmaceutical Co., Ltd. is a municipal state-owned holding listed company and "China time honored brand" enterprise with nearly a hundred years of pharmaceutical history (Stock Code: 002644). Founded in Shanghai in 1929. In 1956, it moved west to Lanzhou. Listed in 2011. At present, the company has developed into a backbone enterprise in the Northwest China traditional Chinese medicine industry, which focuses on the cultivation and processing of traditional Chinese medicine, the research and development of natural drugs and health products, the production and sales of modern dosage forms of traditional Chinese medicine and health food. Up to now, the company has 4 production bases, 1 pharmaceutical science and Technology Industrial Park under construction and 2 wholly-owned subsidiaries. It has total assets of 1009.12 million yuan and net assets of 718.23 million yuan. There are more than 1400 employees, including more than 400 engineering and technical personnel. We have 25 production lines, all of which have passed the national GMP certification. Our production lines have also passed the certification of TGA in Australia, housheng in Japan and Ukrainian product certification authority. At present, there are 345 drug production approval numbers, 10 exclusive products such as Dingxuan pill, Shenrong Guben Huanshao pill, 1 National Traditional Chinese medicine protection variety, 9 invention patents, and 152 kinds of Chinese and Western medicine products with 11 dosage forms such as concentrated pill, big honey pill and tablet. Foci products are well-known at home and abroad for "authentic material selection, excellent technology, accurate curative effect and convenient use". "Foci" brand Liuwei Dihuang pill, Qiju Dihuang pill, Guifu Dihuang pill, Xiaoyao Pill, Xiangsha Yangwei pill and other series of products have been rated as "Gansu famous brand products" for many times. The product field of the company has been expanding, and the large health products represented by donkey hide gelatin and herbal drink "Xiao assistant" have been listed in succession. "Foci" registered trademark is well-known protection, "Minshan" trademark is the key protection trademark of the State Administration for Industry and commerce, "Baolu" and "Shanshu" are famous trademarks of Gansu Province. The company has established good cooperation with many domestic and foreign first-class scientific research institutes, such as Chinese Academy of traditional Chinese medicine, Stockholm University, Tsinghua University, Gansu College of traditional Chinese medicine, etc. At present, there are two key research and development platforms: Gansu Modern Chinese medicine preparation engineering technology research center and Zhongrui natural plant medicine and health product research center. In Zhangxian County, Lintan and other places, there are standardized planting bases for angelica, with a total planting area of nearly 10000 mu. Foci brand has a good market foundation and wide influence at home and abroad. Its international and domestic sales network is increasingly improved. Its products are sold all over the country and exported to 27 countries and regions such as the United States, Australia, Japan and Hong Kong. The number of foreign certification, overseas trademark registration, export coverage and export varieties of its products have long been in the forefront of the same industry. It has been ranked in the middle of China for many years Top 10 pharmaceutical export enterprises. Fosci pharmaceutical is the first enterprise applying for EU drug registration in China. If the concentrated Angelica pill is successfully registered in the EU and passes the EU GMP certification, fosci products are expected to enter the EU market as drugs, and at the same time establish international standards for traditional Chinese medicine. Recently, foci pharmaceutical has been listed in the list of "the first batch of backbone enterprises in the first trial of TCM service trade" by the Ministry of Commerce and other ministries. In the past three years, the company will take the new area project as the support, focus on the construction of international and domestic sales network, seize the opportunity, accelerate the development, and strive to achieve the business income of 1 billion yuan in three years, including the goal of 10 million US dollars for the export of Chinese patent medicine.

本文链接: https://brand.waitui.com/f19a649a3.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

南京商旅:控股股东拟进行改革重组

36氪获悉,南京商旅(600250.SH)公告称,公司控股股东南京旅游集团拟以南京旅游集团为主体,推进南京旅游集团、南京市文化投资控股集团有限责任公司、南京体育产业集团有限责任公司的整合重组工作,打造南京市文旅体商综合开发运营主平台。本次改革重组完成后,公司控股股东和实际控制人不会发生变化,控股股东仍为南京旅游集团(重组完成后可能涉及更名),实际控制人仍为南京市国资委。本次改革重组不涉及上市公司主营业务变更,除了公司正在推进的发行股份及支付现金购买南京旅游集团持有的南京黄埔大酒店有限公司100%股权事项以外,控股股东目前无其他与上市公司有关的文商旅资产或与“苏超”相关体育资产注入计划。

10分钟前

弘信电子:拟发行不超过5亿元科技创新债券

36氪获悉,弘信电子(300657.SZ)公告,公司于2025年7月6日召开董事会,审议通过了《关于公司拟发行科技创新债券的议案》。本次拟发行科技创新债券的规模最高不超过人民币5亿元(含5亿元),发行方式为公开发行或非公开定向发行,发行期限不超过3年(含3年),具体期限由公司与主承销商根据发行时市场情况决定,发行利率根据各期发行时银行间债券市场的市场情况确定。此次发行科技创新债券旨在优化公司债务结构、降低财务风险及扩大生产经营规模。

10分钟前

华创证券给予杭州中泰深冷 “强力买入” 评级

华创证券首次覆盖杭州中泰深冷技术股份有限公司,给予 “强力买入” 评级。目标价定为 20.90 元,较最新价格上涨 39%。(新浪财经)

10分钟前

欧盟内部对美贸易立场分歧明显 德媒称谈判前景不乐观

德国《商报》当地时间7月6日发表评论文章称,欧盟与美国之间围绕新一轮贸易安排的谈判正进入关键阶段。德国与意大利因出口依赖倾向推动尽快达成协议,而法国、西班牙、丹麦等国则对可能的让步表示担忧。欧盟在对美贸易立场上的分歧日益凸显,相关谈判进展缓慢,前景不容乐观。文章指出,尽管欧盟委员会主席冯德莱恩强调希望达成“框架性协议”,以避免美方新一轮关税措施生效,但多方担忧欧方在压力下被迫接受一份“不对等”的协议。多名外交人士直言,目前谈判结果可能对欧盟整体不利。(央视新闻)

10分钟前

宇信科技:持续和在香港的国资银行探讨新的业务系统升级和相关合作机会

36氪获悉,宇信科技(300674.SZ)发布投资者关系活动记录表,自2019年出海以来,公司与各类外资银行前中后台业务系统都有了成功案例,并正积极探索更多产品和业务落地。公司正在支持外资银行的数字化升级,完成相关新一代系统建设;同时还持续和在香港的国资银行,探讨新的业务系统升级和相关合作机会;此外,在非银机构,我们将国内积累的技术能力、产品储备、客户生态资源和各类境外持牌机构洽谈全面科技赋能,支撑业务多层次发展。

10分钟前

本页详细列出关于foci佛慈的品牌信息,含品牌所属公司介绍,foci佛慈所处行业的品牌地位及优势。
咨询